Patient Guide: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 83 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT05503264
Status: 🟢 Enrolling Now
Condition: NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Phase: PHASE3

Where You Can Participate

This study is available at 83 locations across the country.

Top locations include:
  • • Birmingham, Alabama
  • • La Jolla, California
  • • Newport Beach, California
  • • And 80 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis - Join Clinical Trial NCTNCT05503264

How to Join This Clinical Trial - NCTNCT05503264

Learn how to participate in this PHASE3 trial studying an investigational therapy for NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT05503264 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 83 locations. Find a study site near you:

Clinical Research Site

Birmingham, Alabama 35233 - United States

Status: RECRUITING

Clinical Research Site

La Jolla, California 92037 - United States

Status: RECRUITING

Clinical Research Site

Newport Beach, California 92658 - United States

Status: RECRUITING

Clinical Research Site

San Francisco, California 94158 - United States

Status: RECRUITING

Clinical Research Site

Aurora, Colorado 80045 - United States

Status: RECRUITING

Clinical Research Site

Iowa City, Iowa 52242 - United States

Status: RECRUITING

Clinical Research Site

Baltimore, Maryland 21201 - United States

Status: RECRUITING

Clinical Research Site

Baltimore, Maryland 21205 - United States

Status: RECRUITING

Clinical Research Site

Boston, Massachusetts 02115 - United States

Status: RECRUITING

Clinical Research Site

Rochester, Minnesota 55905 - United States

Status: RECRUITING

And 73 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships